BioXcel Therapeutics (NASDAQ: BTAI) reported Q2 EPS of ($0.21), $0.50 better than the analyst estimate of ($0.71). Revenue for the quarter came in at $1.1 million versus the consensus estimate of $662.5 thousand.

For earnings history and earnings-related data on BioXcel Therapeutics (BTAI) click here.